India's Sun Pharma gets final FDA approval to market generic Torsemide table
TMUMBAI (Thomson Financial) - India's Sun Pharmaceutical Industries Ltd said it received final approval from the US Food and Drug Administration for its abbreviated new drug application to market its generic version of Hoffman La Roche Ltd's Demadex Torsemide tablets.
The company added it expects to reach the market shortly with these diuretic products.
In a regulatory filing, Sun Pharma said its generic offerings are the therapeutic equivalents of Hoffman La Roche's Demadex tablets in four strengths.
These have annual sales of about 35 mln usd in the US, it added.
Sun Pharma shares closed 4.54 pct up at 1,192.65 rupees today while the broader Sensex closed 0.19 pct down at 17,773.16. [email protected] net/ran/vs
February 29, 2008